Shopping Cart 0
Cart Subtotal
AED 0

AzurRx BioPharma Inc (AZRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that research and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company's products under development include MS1819, a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP); and AZX1101, a recombinant beta lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. It has partnership with other pharmaceutical companies for the development of proteomics and non-systemic therapeutic biologics. The company has operations in France and the US. AzurRx BioPharma is headquartered in Brooklyn, New York, the US.

AzurRx BioPharma Inc (AZRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

AzurRx BioPharma Raises USD0.64 Million in Financing 10

Licensing Agreements 11

Azurrx Biopharma Enters into Licensing Agreement with Transchem 11

AzurRx BioPharma Enters into Licensing Agreement with TransChem 12

Equity Offering 13

AzurRx BioPharma Plans to Raise up to USD50 Million in Public Offering of Securities 13

AzurRx BioPharma Raises USD10.4 Million in Public Offering of Shares 14

AzurRx BioPharma Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 15

AzurRx BioPharma Files Registration Statement for Public Offering of Shares for USD10 Million 16

AzurRx BioPharma Plans to Raise up to USD10 Million in Public Offering of Shares 17

Azurrx Biopharma Plans to Raise Funds through Public Offering of Shares 18

AzurRx BioPharma Raises USD0.4 Million in Private Placement of Units 19

AzurRx BioPharma Raises USD5 Million in Private Placement of Units 20

AzurRx BioPharma Raises USD5.3 Million in IPO 21

Debt Offering 23

AzurRx BioPharma to Raise USD1.12 Million in Private Placement of 12% Debenture Due 2017 23

AzurRx BioPharma Raises USD9 Million in Private Placement of Notes 24

Acquisition 25

AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 25

AzurRx BioPharma Inc-Key Competitors 27

AzurRx BioPharma Inc-Key Employees 28

AzurRx BioPharma Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Corporate Communications 30

Oct 16, 2017: AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors 30

Sep 25, 2017: AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer 31

Mar 08, 2017: AzurRx Announces Addition of Charles J Casamento to the Board of Directors 32

Clinical Trials 33

Apr 18, 2018: AzurRx BioPharma Announces Positive Preclinical Data with AZX1103 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AzurRx BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

AzurRx BioPharma Raises USD0.64 Million in Financing 10

Azurrx Biopharma Enters into Licensing Agreement with Transchem 11

AzurRx BioPharma Enters into Licensing Agreement with TransChem 12

AzurRx BioPharma Plans to Raise up to USD50 Million in Public Offering of Securities 13

AzurRx BioPharma Raises USD10.4 Million in Public Offering of Shares 14

AzurRx BioPharma Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 15

AzurRx BioPharma Files Registration Statement for Public Offering of Shares for USD10 Million 16

AzurRx BioPharma Plans to Raise up to USD10 Million in Public Offering of Shares 17

Azurrx Biopharma Plans to Raise Funds through Public Offering of Shares 18

AzurRx BioPharma Raises USD0.4 Million in Private Placement of Units 19

AzurRx BioPharma Raises USD5 Million in Private Placement of Units 20

AzurRx BioPharma Raises USD5.3 Million in IPO 21

AzurRx BioPharma to Raise USD1.12 Million in Private Placement of 12% Debenture Due 2017 23

AzurRx BioPharma Raises USD9 Million in Private Placement of Notes 24

AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 25

AzurRx BioPharma Inc, Key Competitors 27

AzurRx BioPharma Inc, Key Employees 28

AzurRx BioPharma Inc, Subsidiaries 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

AzurRx BioPharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that research and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company's products under development include MS1819, a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP); and AZX1101, a recombinant beta lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. It has partnership with other pharmaceutical companies for the development of proteomics and non-systemic therapeutic biologics. The company has operations in France and the US. AzurRx BioPharma is headquartered in Brooklyn, New York, the US.

AzurRx BioPharma Inc (AZRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

AzurRx BioPharma Raises USD0.64 Million in Financing 10

Licensing Agreements 11

Azurrx Biopharma Enters into Licensing Agreement with Transchem 11

AzurRx BioPharma Enters into Licensing Agreement with TransChem 12

Equity Offering 13

AzurRx BioPharma Plans to Raise up to USD50 Million in Public Offering of Securities 13

AzurRx BioPharma Raises USD10.4 Million in Public Offering of Shares 14

AzurRx BioPharma Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 15

AzurRx BioPharma Files Registration Statement for Public Offering of Shares for USD10 Million 16

AzurRx BioPharma Plans to Raise up to USD10 Million in Public Offering of Shares 17

Azurrx Biopharma Plans to Raise Funds through Public Offering of Shares 18

AzurRx BioPharma Raises USD0.4 Million in Private Placement of Units 19

AzurRx BioPharma Raises USD5 Million in Private Placement of Units 20

AzurRx BioPharma Raises USD5.3 Million in IPO 21

Debt Offering 23

AzurRx BioPharma to Raise USD1.12 Million in Private Placement of 12% Debenture Due 2017 23

AzurRx BioPharma Raises USD9 Million in Private Placement of Notes 24

Acquisition 25

AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 25

AzurRx BioPharma Inc-Key Competitors 27

AzurRx BioPharma Inc-Key Employees 28

AzurRx BioPharma Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Corporate Communications 30

Oct 16, 2017: AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors 30

Sep 25, 2017: AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer 31

Mar 08, 2017: AzurRx Announces Addition of Charles J Casamento to the Board of Directors 32

Clinical Trials 33

Apr 18, 2018: AzurRx BioPharma Announces Positive Preclinical Data with AZX1103 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AzurRx BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8

AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

AzurRx BioPharma Raises USD0.64 Million in Financing 10

Azurrx Biopharma Enters into Licensing Agreement with Transchem 11

AzurRx BioPharma Enters into Licensing Agreement with TransChem 12

AzurRx BioPharma Plans to Raise up to USD50 Million in Public Offering of Securities 13

AzurRx BioPharma Raises USD10.4 Million in Public Offering of Shares 14

AzurRx BioPharma Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 15

AzurRx BioPharma Files Registration Statement for Public Offering of Shares for USD10 Million 16

AzurRx BioPharma Plans to Raise up to USD10 Million in Public Offering of Shares 17

Azurrx Biopharma Plans to Raise Funds through Public Offering of Shares 18

AzurRx BioPharma Raises USD0.4 Million in Private Placement of Units 19

AzurRx BioPharma Raises USD5 Million in Private Placement of Units 20

AzurRx BioPharma Raises USD5.3 Million in IPO 21

AzurRx BioPharma to Raise USD1.12 Million in Private Placement of 12% Debenture Due 2017 23

AzurRx BioPharma Raises USD9 Million in Private Placement of Notes 24

AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 25

AzurRx BioPharma Inc, Key Competitors 27

AzurRx BioPharma Inc, Key Employees 28

AzurRx BioPharma Inc, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

AzurRx BioPharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.